Insights
Search Results
Client Highlights
4.20.26
Wilson Sonsini Advises Novo Holdings on Route 92 Medical’s $50 Million Growth Financing
On April 7, 2026, Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, announced a $50 million growth financing led by Novo Holdings. New investor Sectoral Asset Management and existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group joined in the financing round. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.
Client Highlights
3.13.26
Wilson Sonsini Advises Urgently on Acquisition by Agero
On March 13, 2026, Agero, a software-enabled driver safety services and technology company, announced that it has entered into an agreement to acquire Urgent.ly (Urgently), a digital software platform that provides roadside and mobility assistance, for a cash price of $5.50 per share. The tender offer and merger are expected to close by the end of May 2026, subject to satisfaction of customary closing conditions. Wilson Sonsini Goodrich & Rosati advised Urgently on the transaction.
Client Highlights
2.13.26
Firm Advises Microchip Technology on Offering of $900 Million of Convertible Senior Notes
On February 11, 2026, Microchip Technology completed an offering of $900 million aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Microchip had granted to the initial purchasers to purchase up to an additional $100 million of notes. In connection with the offering, Microchip entered into privately negotiated capped call transactions with certain of the initial purchasers or their respective affiliates and other financial institutions.
Client Highlights
12.15.25
Wilson Sonsini Advises Tenaya Therapeutics on Pricing of Public Offering
On December 11, 2025, Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop, and deliver potentially curative therapies that address the underlying causes of heart disease, announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised Tenaya on the transaction.
Client Highlights
4.09.25
Wilson Sonsini Advises TigaTx on Acquisition by Epsilogen
On April 7, 2025, Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibody therapeutics, announced that it has completed the acquisition of TigaTx, a Boston-based biotechnology company developing engineered immunoglobulin A (IgA) antibodies, to create the world’s leading pan-isotype cancer antibody company.
Client Highlights
3.25.25
Wilson Sonsini Advises Microchip on Offering of $1.48 Billion of Depositary Shares
On March 25, 2025, Microchip Technology completed a mandatory convertible preferred stock offering of $1.48 billion of depositary shares, each representing a 1/20th interest in a share of 7.50% Series A Mandatory Convertible Preferred Stock, in an underwritten public offering. The offering amount included the exercise in full of the over-allotment option that Microchip had granted to the underwriters to purchase up to an additional $135 million of depositary shares. In connection with the offering, Microchip entered into privately negotiated capped call transactions with one or more of the underwriters and other financial institutions. Microchip is one of the first technology companies to use this mandatory convertible preferred stock structure with a capped call feature.
Client Highlights
1.10.25
Wilson Sonsini Advises Prudentia Sciences on $7 Million Funding as Company Emerges from Stealth
On January 9, 2025, Prudentia Sciences, an AI-powered technology platform for life sciences, emerged from stealth supported by $7 million in funding. Google Ventures led the financing with participation from Iaso Ventures and Virtue. Wilson Sonsini Goodrich & Rosati advised Prudentia Sciences on the transaction.
Client Highlights
12.13.24
Wilson Sonsini Advises BioSapien on $5.5 Million Pre-Series A Funding
On December 13, 2024, BioSapien, an Abu Dhabi-based biotech startup focused on drug delivery for localized cancer treatment, announced the successful completion of a $5.5 million pre-Series A funding round. The round was led by Global Ventures, a prominent MENA-based venture capital firm, with additional backing from Dara Holdings. Wilson Sonsini Goodrich & Rosati provided legal counsel to BioSapien on the transaction.
Client Highlights
12.13.24
Wilson Sonsini Advises Lumos Pharma on Tender Offer and Merger with Double Point Ventures
On December 12, 2024, Lumos Pharma, a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures (DPV) announced the successful completion the previously announced tender offer for Lumos Pharma's shares, with 75.62 percent of shares tendered. The purchase price of $4.25 per share represents a total equity value of approximately $38 million. Following the acceptance of the shares offered in the tender, DPV successfully acquired enough shares of Lumos Pharma's common stock to finalize the merger. Wilson Sonsini Goodrich & Rosati advised Lumos Pharma on the transaction.
Client Highlights
5.31.24
Wilson Sonsini Advises Microchip Technology in Private Offering of $1.25B of Convertible Senior Notes
On May 31, 2024, Microchip Technology (Nasdaq: MCHP) completed an offering of $1.25 billion aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Microchip had granted to the initial purchasers to purchase up to an additional $150 million of notes. In connection with the offering, Microchip entered into privately negotiated capped call transactions with one or more of the initial purchasers and other financial institutions.
Client Highlights
3.08.24
Wilson Sonsini Represents Microchip in $1 Billion Investment Grade Notes Offering
On March 5, 2024, Microchip Technology Incorporated (Microchip) priced an offering of $1 billion in aggregate principal amount of its 5.050% senior notes due 2029 (the notes). The notes are and will be guaranteed by each of Microchip’s existing and future subsidiaries that is or becomes an obligor under Microchip’s existing senior credit facilities. The sale of the notes closed on March 7, 2024. Microchip intends to use the net proceeds from the sale of the notes to repay a portion of the debt outstanding under its commercial paper program and the payment of fees and expenses related to the offering of the notes.
Client Highlights
2.13.24
Wilson Sonsini Advises Tenaya Therapeutics on $50 Million Underwritten Offering
On February 8, 2024, Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced the pricing of an underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 2,222,271 shares at a purchase price of $4.499 per pre-funded warrant. Tenaya anticipates gross proceeds from the offering to be approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised Tenaya Therapeutics on the transaction.